Persistence of glaucoma medical therapy in the Glasgow glaucoma database

British Journal of Ophthalmology

Volumn 95, Issue 7, 2011, Pages 966-970

  Rahman, M Q ^a   Abeysinghe, S S ^b   Kelly, S ^c   Roskell, N S ^b   Shannon, P R ^b   Abdlseaed, A A ^d   Montgomery, D M I ^e  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b RTI HEALTH SOLUTIONS   (United States)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^e GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAXOLOL; BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; TIMOLOL; TRAVOPROST;

ADULT; AGED; ALGORITHM; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG CHOICE; DRUG TREATMENT FAILURE; FACTUAL DATABASE; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; OPEN ANGLE GLAUCOMA; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT PLANNING;

ALGORITHMS; ANTIHYPERTENSIVE AGENTS; BETAXOLOL; CLINICAL PROTOCOLS; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; GLAUCOMA; HUMANS; MALE; OCULAR HYPERTENSION; QUINOXALINES; SCOTLAND; TIMOLOL;

EID: 79959362558     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.188607     Document Type: Article

References (22)

1. Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93. (Pubitemid 26158268)
2. Coffey M, Reidy A, Wormald R, et al. Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol 1993;77:17-21. (Pubitemid 23031807)
3. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992;99:1499-504.
4. Reidy A, Minassian DC, Vafidis G, et al. Prevalence of serious eye disease and visual impairment in a north London population: population based, cross sectional study. BMJ 1998;316:1643-6. (Pubitemid 28247994)
5. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79. (Pubitemid 36105431)
6. Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Ophthalmol 2003;14:86-90. (Pubitemid 36584227)
7. Rotchford AP, Murphy KM. Compliance with timolol treatment in glaucoma. Eye (Lond) 1998;12:234-6. (Pubitemid 28263862)
8. MacKean JM, Elkington AR. Compliance with treatment of patients with chronic open-angle glaucoma. Br J Ophthalmol 1983;67:46-9. (Pubitemid 13172509)
9. Konstas AG, Maskaleris G, Gratsonidis S, et al. Compliance and viewpoint of glaucoma patients in Greece. Eye (Lond) 2000;(14 Pt 5):752-6.
10. Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 1995;26:233-6.
11. Rahman MQ, Montgomery DM, Lazaridou MN. Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years' experience. Br J Ophthalmol 2009;93:1572-5.
12. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
13. Dasgupta S, Oates V, Bookhart BK, et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002;8(10 Suppl):S255-61.
14. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;140:598-606.
15. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137(1 Suppl):S3-12.
16. Shaya FT, Mullins CD, Wong W, et al. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care 2002;8(10 Suppl):S271-7.
17. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141(1 Suppl):S28-33.
18. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther 2003;25:1172-85. (Pubitemid 36532585)
19. Reardon G, Schwartz GF, Kotak S. Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy. BMC Ophthalmol 2010;10:5.
20. Schuman JS, Horwitz B, Choplin NT, et al. 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol 1997;115:847-52.
21. LeBlanc RP. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 1998;105:1960-7. (Pubitemid 28509740)
22. Osborne SA, Montgomery DM, Morris D, et al. Alphagan allergy may increase the propensity for multiple eye-drop allergy. Eye (Lond) 2005;19:129-37. (Pubitemid 40309497)